Nidlegy™ Phase III PIVOTAL trial meets the study’s primary o...

Intratumoral Nidlegy followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming international medical meeting and submitted to peer-reviewed journal, as well as to regulatory authorities Nidlegy is also currently developed for the treatment of high-risk locally advanced basal cell carcinoma and other types of non-melanoma skin cancers SIENA, Italy and MUMBAI, India, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) and Sun Pharmaceutical Industries Limited (...